AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00170274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activation of preventive and therapeutic algorithms for treatment of AF
Description: Algorithms in At 500 or Enrhyhtm for prevention and termination of Atrial Fibrillation
Study NCT00170274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AF Prevention and Therapy Algorithms On
Description: Activation of AF-prevention and termination algorithms in AT 500 or EnRhyhtm
Study NCT03484624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Description: All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
Study NCT01883739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parental Presence at Handover Rounds
Study NCT02287688 — intervention group
Intervention type: BIOLOGICAL
Intervention: Meningococcal quadrivalent CRM-197 conjugate vaccine
Description: This study is strictly observational. Decisions of vaccination are made by health care providers.
Study NCT02603510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR342434
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study NCT02603510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study NCT03351634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck
Description: The ACT system is a permanent implant designed for the correction of incontinence in patients.
Study NCT04140812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mass spectrometry (LC-MS/MS)
Description: Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (\<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS) for 125 proteins.
Study NCT04140812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: mass spectrometry (LC-MS/MS)
Description: Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (\<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS) for 125 proteins.
Study NCT02697916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 81mg of aspirin daily vs. 325mg of aspirin daily
Study NCT00293800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study NCT00293800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
Description: Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
Study NCT00293800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5% Ophthalmic Solution
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
Study NCT00293800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timolol Vehicle
Description: Placebo
Study NCT02100735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedation protocol
Description: Nursing driven sedation protocol
Study NCT02100735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation protocol
Description: Nursing driven sedation protocol
Study NCT01759719 — intervention group
Intervention type: DEVICE
Intervention: coronary angioplasty with PtCr stent implantation
Description: PCI with deployment of at least 1 PtCr stent
Study NCT02309450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .Asunaprevir, Daclatasvir and BMS - 791325
Description: All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.
Study NCT04170946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talazoparib in Combination with Low Dose Radiotherapy (RT)
Description: Dose escalation model to determine the safety and MTD of talazoparib in combination with low dose RT.
Study NCT03972501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZR-MD-001 Vehicle
Description: AZR-MD-001 is an ophthalmic ointment
Study NCT03972501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 Active Dose
Description: AZR-MD-001 is an ophthalmic ointment
Study NCT04563637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computer based vision application by video
Description: patients will be tested by computer based analysis of a video as well as by dexa scan.
Study NCT04563637 — intervention group
Intervention type: RADIATION
Intervention: whole body dual energy x-ray absorptiometry scan
Description: subjects will receive a whole body dual energy x-ray absorptiometry scan to measure their body fat percentage
Study NCT00349193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: laquinimod 0.3
Description: laquinimod 0.3mg
Study NCT00349193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: laquinimod 0.6
Description: laquinimod 0.6mg
Study NCT00349193 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded Placebo
Study NCT04420247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: 5 days of treatment with Chloroquine + Standard Care
Study NCT04420247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 5 days of treatment with Hydroxychloroquine + Standard Care
Study NCT04420247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Standard Care according to Brazilian Guidelines for treating COVID-19
Study NCT03714997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Walking training
Description: Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
Study NCT03714997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Walking training
Description: Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
Study NCT03838731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1908-1909
Description: Single subcutaneous (SC) dose of REGN1908 and REGN1909
Study NCT03838731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single subcutaneous (SC) dose of matching placebo
Study NCT03752177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3415244
Description: Administered IV
Study NCT01478451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise will be performed for 10 minutes at the left or right trapezius (randomized)
Study NCT01478451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: massage will be provided for 10 minutes at the left or right trapezius (randomized)
Study NCT00006244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00006244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Given SC
Study NCT04465266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone
Description: tablets
Study NCT00006244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
Study NCT00006244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation
Description: Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
Study NCT03216369 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: MRI perfusion imaging
Study NCT01220726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Botox injection
Study NCT01220726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study NCT02579382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: 300 mg tablets administered orally once daily
Study NCT02931422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Conditional cash transfer upon HIV testing
Study NCT03745677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced and Integrated MicroSystems (AIMS) interventions
Description: Each of 4 sites is receiving mentorship from nurse and physician with expertise in implementing similar interventions. The AIMS interventions consist of 1) unit-based physician teams, 2) unit nurse-physician co-leadership, 3) enhanced interprofessional rounds, 4) unit-level performance reports, and 5) patient engagement activities.
Study NCT02579382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TDF
Description: 300 mg tablets administered orally once daily
Study NCT02579382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Tablets administered orally once a week (every 7 days) for 12 doses
Study NCT02579382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally once a week (every 7 days) for 12 doses
Study NCT03815435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Controlled hypotension
Description: Controlled hypotension will be administered according to the clarity of the surgical field.
Study NCT01212159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Monitoring Lipid Analyzer
Description: The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
Study NCT03818009 — intervention group
Intervention type: OTHER
Intervention: Assessment document
Description: The anesthesiologist will evaluate through his sheet women's cognitive functions.
Study NCT04676152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Noninvasive Blood Pressure Device
Description: Non-invasive blood pressure device
Study NCT01532258 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go! Foods for You without Weekly MA Support.
Description: * Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* Each day participants receive educational materials related to the nutritional science of a Mediterranean diet. Each week (1) a new theme for the daily educational materials is presented and (2) participants are asked to schedule activities on a built in calendar and practice the activity throughout the week.
Study NCT01532258 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go! Foods for You with Weekly MA Support.
Description: * Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* In addition to the 8-week online program, participants receive weekly support by Medical Assistants (MA) over the phone or by email to establish a relationship and maintain program adherence by discussing the previous week's behavioral goals and setting weekly behavioral goals.
Study NCT01299896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coordinated Care
Description: CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
Study NCT01299896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard therapy to help participants with smoking cessation.
Study NCT02706145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social norming campaign
Description: community-level, three-year social norming campaign, using traditional and emerging media, aimed at changing norms of violence among youth 10-24
Study NCT03139409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adhesive bond with chlorhexidine
Description: Peak® Universal Bond (ultradent, 505 West 10200 South, South Jordan, UT 84095،USA ) light-Cured Adhesive with Chlorhexidine (0.2%), 7.5% filler, phosphate and containing hydroxyethyl methacrylate with ethyl alcohol as the carrier. its viscosity has been optimized for minimal film thickness (2μm) and superior strength. using self etch adhesive with chlorexidine as one step in the bonding component may give chance to proper penetration of resin tags, decrease the micro-organisms due to the antibacterial effect of chlorexidine (Bin-Shuwaish, 2016) and also the addition of chlorexidine in bonding system may be an excellent tool to increase the stability of collagen fibrils within the hybrid layer against host-derived metaloproteinases (MMP) without the need for additional steps for the bonding protocol (Stanislawczuk, et al., 2009), which results in better durability and good restorations with decreasing the incidence of recurrent caries
Study NCT03139409 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Time variable
Description: Diagnosis and follow up will be immediate , 6 months later and 1 year
Study NCT03181945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 4 weeks
Description: Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
Study NCT03181945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 12 weeks
Description: Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
Study NCT04162405 — intervention group
Intervention type: BEHAVIORAL
Intervention: Tinnitus Handicap Inventory Test
Description: A prospective cohort nonrandomized study of non-masked parallel paired groups. The data will be collected from an electronic database that is filled in during diagnostic processing. During the diagnostic processing, TSI and THI questionnaires will be filled in, a tone audiogram (TA) and DPOAE will be performed.
Study NCT02748759 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPM
Description: 15 repetitions of flexo-extensión with a commercially available CPM device (Kinetec Advanced Prima)
Study NCT02748759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual mobilization
Description: Manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist
Study NCT02501941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
Study NCT00639106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alloderm, Questionnaires
Description: All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
Study NCT03525262 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 30Gy (Gray) planning target volume (PTV)
Description: PTV1_30Gy represents a 3mm expansion on the prostate (and proximal seminal vesicle per physician discretion), excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).
Study NCT02834767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genioglossis Strength Trainer
Description: The genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. The device can be set to a specific pressure resistance ranging from 10 to 40 Newtons. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
Study NCT02834767 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Genioglossis Strength Trainer
Description: The placebo genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. Whereas the pressure loaded spring in the active trainer can be set to a wide range of pressures, the placebo trainer has a maximum resistance of 5 Newtons. The device is set to a specific pressure resistance of 5 Newtons at all times. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
Study NCT02412735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rexlemestrocel-L
Description: Rexlemestrocel-L injection
Study NCT02412735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rexlemestrocel-L + HA Mixture
Description: Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected
Study NCT02412735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline control solution
Study NCT01508949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
Study NCT01508949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
Study NCT04329637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrative healt care
Description: Meditation and use of a care cordinator
Study NCT04219995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone sodium succinate
Description: Methylprednisolone sodium succinate will be re-constituted in simple syrup in a concentration of 80mg/mL and will be administered orally at 20mg/kg (max 1000mg) for days 1, 2, and 3 of the intervention phase of the study.
Study NCT04219995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone sodium succinate
Description: Methylprednisolone sodium succinate will be re-constituted in simple syrup in a concentration of 80mg/mL and will be administered orally at 20mg/kg (max 1000mg) for days 1, 2, and 3 of the intervention phase of the study.
Study NCT04219995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo used in this study will be simple syrup.
Study NCT04219995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used in this study will be simple syrup.
Study NCT01008553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
Study NCT01008553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
Study NCT00400998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Propionate
Description: Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:~- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate.
Study NCT00400998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched FPANS placebo
Description: Subjects will receive the following placebo treatment regimen over one of two dosing periods within each of the three study phases:~* Intranasal FPANS placebo once daily for 8 to 14 days (i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL.
Study NCT06784362 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study
Study NCT06787534 — intervention group
Intervention type: OTHER
Intervention: No Interventions
Study NCT06785896 — intervention group
Intervention type: PROCEDURE
Intervention: Angle Class II unilateral, treated by carriere motion appliance
Description: This treatment was unilateral, with dental composite bites ramps behind canines
Study NCT00639106 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without ALLODERM, Questionnaires
Description: A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.